Search
for
Sort by
Research 31–60 of 1000+
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- An overview of management of drug-induced hair and nail disorders
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
- Skin Biology and Ageing
- Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
- The PDGF/PDGFR pathway as a drug target
- Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
- Nilontinib induced keratosis pilaris atrophicans
- Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
- Rapid hair depigmentation in patient treated with pazopanib
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Gefitinib-induced hair alterations: Figure 1
- Nilotinib-induced generalized keratosis pilaris: Report of a rare case
- Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature
- The Dark Side of Gefitinib: Reflectance Confocal Microscopy Applied to Hair Hyperpigmentation
- Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female
- Drug-induced hair pigmentation: Clinical perspectives and updates
- Drug-induced scarring and permanent alopecia
- Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
- Targeted Treatments of Non-Small Cell Lung Cancer (NSCLC): Skin Toxicity
- Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
- Axitinib-induced repigmentation of grey hair in a patient with metastatic renal cell carcinoma
- Hair Re-Pigmentation After Nilotinib
- Are all adverse effects undesirable? a case of chemotherapy induced adverse effect- an exception!?
- 854 Dermal fibroblasts enhance growth factors production by androgens, and modulate keratinocyte proliferation and differentiation
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development